InvestorsHub Logo
Followers 172
Posts 17650
Boards Moderated 0
Alias Born 03/02/2012

Re: None

Wednesday, 09/12/2018 8:10:09 AM

Wednesday, September 12, 2018 8:10:09 AM

Post# of 19459
GOVX highlights going into 2019


CEO message very promising! Big things coming!
https://www.geovax.com/images/180910_Shareholder_Message_FINAL.pdf


Great video about GOVX potential and partners!
https://vimeo.com/281801876


New CEO promises to get updates out to shareholders and build value!
https://www.geovax.com/images/180910_Shareholder_Message_FINAL.pdf


Chart ready to bounce UP!
http://stockcharts.com/h-sc/ui?s=govx


Received FAST TRACK Status for vaccine recently!

http://www.wistv.com/story/37919705/geovax-awarded-nih-fast-track-phase-iii-grant-to-advance-lassa-fever-vaccine


Pipeline to die for!

https://www.geovax.com/clinical-pipeline.html


Just won BEST BIOTECH AWARD TOO! GOVS is a REAL CO! Real BOD! REAL REVS coming!

https://globenewswire.com/news-release/2018/04/05/1465727/0/en/GeoVax-Recognized-as-Best-Biotech-at-Vaccine-Industry-Excellence-Awards-during-World-Vaccine-Congress.html


FOX NEWS! (1:37 in)
http://video.foxnews.com/v/4748774457001/?#sp=show-clips


Real BOD!
https://www.geovax.com/corporate-governance/board-of-directors-corporate-governance.html

About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company's HIV vaccine for the clade B epidemic in the Americas and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network. Preclinical programs are focused on preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit https://www.geovax.com/.



Zacks says, .25 valuation!
https://www.geovax.com/images/GOVX_SCIR-2017-08-22.PDF

Too much good news coming out for GOVX to go unnoticed, imho!

https://finance.yahoo.com/news/geovax-reports-significant-advance-hiv-180000573.html
https://insiderfinancial.com/geovax-labs-inc-otcmktsgovx-just-hit-a-major-hiv-milestone
https://www.geovax.com/clinical-pipeline.html

Significant advances from Duke Medical, Unv. Penn, Alamos! This is HUGE!!!

"This as an important advance in the development of a vaccine with the potential to elicit broadly neutralizing antibody to the CD4 binding site," Dr. Robinson continued. "We intend to push this technology forward for the development of a vaccine for the clade C subtype of HIV that is devastating populations in Africa."



A/S 600M, Float, 105M

http://www.otcmarkets.com/stock/GOVX/profile
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GOVX News